Abstract
Platelet-activating factor (PAF) induces pulmonary edema and has a key role in acute lung injury (ALI). Here we show that PAF induces pulmonary edema through two mechanisms: acid sphingomyelinase (ASM)-dependent production of ceramide, and activation of the cyclooxygenase pathway. Agents that interfere with PAF-induced ceramide synthesis, such as steroids or the xanthogenate D609, attenuate pulmonary edema formation induced by PAF, endotoxin or acid instillation. Our results identify acid sphingomyelinase and ceramide as possible therapeutic targets in acute lung injury.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antibodies / metabolism
-
Antibodies / therapeutic use
-
Bridged-Ring Compounds / metabolism
-
Ceramides / metabolism*
-
Dexamethasone / metabolism
-
Female
-
Glucocorticoids / metabolism
-
In Vitro Techniques
-
Mice
-
Mice, Inbred BALB C
-
Norbornanes
-
Phosphodiesterase Inhibitors / metabolism
-
Platelet Activating Factor / metabolism*
-
Pulmonary Edema / drug therapy
-
Pulmonary Edema / metabolism*
-
Rats
-
Rats, Wistar
-
Sphingomyelin Phosphodiesterase / antagonists & inhibitors
-
Sphingomyelin Phosphodiesterase / metabolism*
-
Thiocarbamates
-
Thiones / metabolism
Substances
-
Antibodies
-
Bridged-Ring Compounds
-
Ceramides
-
Glucocorticoids
-
Norbornanes
-
Phosphodiesterase Inhibitors
-
Platelet Activating Factor
-
Thiocarbamates
-
Thiones
-
tricyclodecane-9-yl-xanthogenate
-
Dexamethasone
-
acid sphingomyelinase-1
-
Sphingomyelin Phosphodiesterase